Genmab — November 2016
-
-
Når I er tilmeldt kan I følge med i Q&A chatten. Der kommer et transcript senere.
-
Noget spændende i abstracts?
-
hvilken dag i næste uge er CMD i usa ?
-
Kan ikke nå det. Ryger på motorvejen igen. Prøver lige inden jeg starter Q&A. Skriv endelig nogle linjer om indholdet.
-
Tjek lige denne her: overall response rates of close to 35% were seen with DARA-POM-D regimen among patients that are refractory to both DARA and POM. While recapturing the responses with combination therapy DARA-POM-D among patients that are refractory to the individual agents (Figure 1) is provocative
-
tror at AB har fået lukket for kreditten
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind